Simplex Trading
DSGN icon

Simplex Trading’s Design Therapeutics DSGN Stock Holding History

Simplex Trading’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-263
Closed -$1K – 8880
2025
Q1 		$1K Sell
263
-4,905
-95% -$23.4K ﹤0.01% 8184
2024
Q4 		$31K Sell
5,168
-2,434
-32% -$14.1K ﹤0.01% 6315
2024
Q3 		$40K Buy
7,602
+6,307
+487% +$29.7K ﹤0.01% 6079
2024
Q2 		$4K Sell
1,295
-3,724
-74% -$14.5K ﹤0.01% 7970
2024
Q1 		$20K Buy
5,019
+3,057
+156% +$8.16K ﹤0.01% 7081
2023
Q4 		$5K Buy
1,962
+1,697
+640% +$3.89K ﹤0.01% 7840
2023
Q3 		$0 Sell
265
-117
-31% -$546 ﹤0.01% 8898
2023
Q2 		$2K Sell
382
-155
-29% -$949 ﹤0.01% 8392
2023
Q1 		$3K Buy
+537
New +$4.02K ﹤0.01% 8293

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Simplex Trading's DSGN Position: Q2 2025 in Review

Simplex Trading sold out of Design Therapeutics (DSGN) in Q2 2025, closing a stake of 263 shares — an estimated $1K sold.

Simplex Trading first reported a position in DSGN in Q1 2023 and held it in 9 quarters. The position peaked at $40K in Q3 2024. 92 funds tracked by Wall St. Rank hold DSGN as of Q2 2025.

  • Simplex Trading reported no remaining Design Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Simplex Trading sold 263 Design Therapeutics shares in Q2 2025, an estimated $1K.
  • Simplex Trading first reported a position in Design Therapeutics in Q1 2023 and held it in 9 quarters.
  • Simplex Trading's Design Therapeutics position peaked at $40K in Q3 2024.
  • 92 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2025.

Based on Simplex Trading's 13F filing for Q2 2025, filed 5 Aug 2025.